Skip to main content

Table 3 Summary of 8 significant CpG sites with different methylation change rates over time for individuals with T2D compared to those with NGT

From: Longitudinal association between DNA methylation and type 2 diabetes: findings from the KORA F4/FF4 study

Probe

Estimate1 (%)

Estimate2 (%)

Estimate3 (%)

pvalue

p_FDR

Gene

Gene_group

cg10442325

− 0.86

− 0.71

0.14

3.81E-05

0.002

#

#

cg15418499

− 0.98

− 0.81

0.17

8.19E-04

0.023

IL18

5’UTR

cg20507228

− 1.16

− 0.96

0.19

1.10E-03

0.023

MAN2A2

Body

cg04334723

− 0.79

− 0.68

0.10

2.15E-03

0.031

CALR

Body

cg20346503

− 1.22

− 1.31

− 0.09

2.48E-03

0.031

#

#

cg19693031

− 1.01

− 1.15

− 0.14

3.40E-03

0.031

TXNIP

3’UTR

cg20661985

− 1.39

− 1.25

0.13

3.46E-03

0.031

C20orf3

Body

cg00574958

− 0.17

− 0.10

0.07

6.02E-03

0.048

CPT1A

5’UTR

  1. Probe: Unique identifier from the Illumina CG database; Estimate1: the estimate of follow-up time indicating the methylation change rate per year for individuals with NGT; Estimate2: the methylation change rate per year for individuals with T2D by adding Estimate1 and Estimate3; Esimate3: the estimate of the interaction term between diabetes and follow-up time indicating the difference of methylation change rates between NGT and T2D; p_FDR: Benjamini-Hochberg corrected p value; Gene: Target gene name from the UCSC database. Gene_Group: Gene region feature category describing the CpG position from UCSC
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840